Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

162.30USD
22 Feb 2017
Change (% chg)

$0.15 (+0.09%)
Prev Close
$162.15
Open
$161.80
Day's High
$163.40
Day's Low
$161.21
Volume
271,736
Avg. Vol
485,298
52-wk High
$186.87
52-wk Low
$119.37

ILMN.OQ

Chart for ILMN.OQ

About

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions,... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $23,744.49
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  ILMN.OQ Industry Sector
P/E (TTM): 51.92 52.89 29.35
EPS (TTM): 3.13 -- --
ROI: 13.16 7.57 12.97
ROE: 22.87 11.40 14.11

BRIEF-Illumina says board increased size of board from 10 to 11 members

* On February 18, 2017, board increased size of board from ten to 11 members and elected John Thompson to board - SEC filing Source text (http://bit.ly/2m4NjYm) Further company coverage:

Feb 21 2017

BRIEF-Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017

* Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing

Feb 13 2017

BRIEF-Illumina Q4 non-gaap earnings per share $0.85

* Illumina reports full financial results for fourth quarter and fiscal year 2016

Jan 31 2017

BRIEF-Illumina elects Caroline Dorsa to serve on board

* Illumina Inc - effective as of Jan 26, 2017 increased size of board from nine to ten members and elected Caroline Dorsa to serve on board - SEC filing Source text: (http://bit.ly/2k1ulOq) Further company coverage:

Jan 27 2017

BRIEF-Illumina names Caroline Dorsa to its board of directors

* Illumina names Caroline Dorsa to its board of directors, adding over 30 years of leadership experience in the healthcare, telecommunications and energy industries Source text for Eikon: Further company coverage:

Jan 27 2017

BRIEF-Caredx to acquire SBT Resolver HLA typing products from Illumina

* Caredx to acquire SBT Resolver HLA typing products from Illumina Source text for Eikon: Further company coverage:

Jan 24 2017

BRIEF-Illumina, NRGene collaborate to accelerate development of new molecular breeding tools for cattle to support global food production

* Illumina, NRGene collaborate to accelerate development of new molecular breeding tools for cattle to support global food production Source text for Eikon: Further company coverage:

Jan 12 2017

Judge in gene-sequencing lawsuit blocks Illumina's claim against Cornell

A federal judge in Delaware has blocked biotechnology company Illumina from filing claims that Cornell University employees deceived the U.S. Patent and Trademark Office in order to obtain a gene-sequencing patent that the university accuses Illumina of infringing.

Jan 12 2017

Illumina, Qiagen to square off over GeneReader ban

Diagnostic technology company Qiagen NV will try to persuade the U.S. Court of Appeals for the Federal Circuit on Thursday to throw out an injunction barring the sale of its year-old GeneReader, the company's entry into the rapidly growing gene-sequencing market.

Jan 11 2017

New Illumina tech could usher in $100 gene-sequencing era

Shares of Illumina Inc rose 16 percent on Tuesday, after the company unveiled new technology, which is expected to eventually reduce the cost of sequencing to $100 per human genome, prompting a slew of price target increases.

Jan 10 2017

More From Around the Web

Earnings vs. Estimates